These trials enrolled high-risk T2DM patients and showed that SGLT2 inhibitors only slightly reduce major adverse cardiovascular events (MACE), but all trials reported a highly significant ~32% relative reduction in risk of hospitalization for HF with no heterogeneity [16]. Here, SLC5A2 is linked to hydrops fetalis.